Angiopoietin-like protein 4 (ANGPTL4), a newly developed diagnostic and prognostic biomarker, acts as a potential therapy target for renal cell carcinoma, prostate cancer and hepatocellular carcinoma [27,28,29]. Here, ANGPTL4 is linked to Familial prostate cancer.